UCLA review of 565 studies finds thin evidence for six wellness peptides

The wire

1. 01A UCLA Health review of 565 studies on BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu found little evidence of meaningful benefit; over two-thirds were animal studies.
2. 02Reviewers flagged safety concerns including an MK-677 trial stopped over congestive heart failure risk, and warned unapproved products may contain undisclosed substances.
3. 03The roundup also notes TRM Labs and Chainalysis research linking China-based fentanyl precursor suppliers to the peptide trade, and warnings against black-market retatrutide.

From the source

September 8, 2026: Researchers say evidence that peptides are effective “is just not there”

A UCLA Health review of 565 studies on six popular unapproved peptides— BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu—found little evidence that they provide meaningful benefits. Researchers say more than two-thirds of the studies were conducted only in animals, while the limited human research was generally low-quality. They flagged potential safety concerns, including a trial of MK-67